Skip to main content
Presentation
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. Spanish Society of Rheumatology (SER), Bilbao, Spain, May 2017.
Spanish Society of Rheumatology (SER) (2017)
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
May, 2017
Citation Information
Philip Mease and et.al.. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. Spanish Society of Rheumatology (SER), Bilbao, Spain, May 2017." Spanish Society of Rheumatology (SER) (2017)
Available at: http://works.bepress.com/philip-mease/267/